A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

NCT06035497 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory T-cell Lymphomas

Interventions

DRUG: BMS-986369

Sponsor

Bristol-Myers Squibb